Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04071236 · ClinicalTrials.gov registry record · Phase 1

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

A Phase 1 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Malignant Neoplasm in the Bone, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 1
Development phase
90
Enrollment target
20
Study locations

NCT04071236: Recruiting Phase 1 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Malignant Neoplasm in the Bone, sponsored by National Cancer Institute (NCI).

NCT04071236 is a Phase 1 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Malignant Neoplasm in the Bone that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 90 participants, below the 175-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04071236, a Phase 1 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Malignant Neoplasm in the Bone, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as radium-223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to find out the better treatment between radium-223 dichloride alone, radium-223 dichloride in combination with M3814, or radium-223 dichloride in combination with both M3814 and avelumab, to lower the chance of prostate cancer growing or spreading in the bone, and if this approach is better or worse than the usual approach for advanced prostate cancer not responsive to hormonal therapy.

Conditions Studied

Stage IVB Prostate Cancer AJCC v8 Metastatic Malignant Neoplasm in the Bone Metastatic Castration-resistant Prostate Carcinoma Metastatic Malignant Neoplasm in the Lymph Nodes

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Bone Scan
  • DRUG Avelumab

Study Locations (20)

Florida

  • UM Sylvester Comprehensive Cancer Center at Aventura - Aventura
  • UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
  • University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
  • UM Sylvester Comprehensive Cancer Center at Kendall - Miami
  • UM Sylvester Comprehensive Cancer Center at Plantation - Plantation

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Los Angeles General Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • University of California Davis Comprehensive Cancer Center - Sacramento

Kansas

  • University of Kansas Clinical Research Center - Fairway
  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Cancer Center-Overland Park - Overland Park
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital/Winship Cancer Institute - Atlanta
  • Emory Saint Joseph's Hospital - Atlanta

Kentucky

  • University of Kentucky/Markey Cancer Center - Lexington

Michigan

  • Wayne State University/Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2020-10-14
Est. Completion 2026-04-30
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What NCT04071236 shows while recruiting

NCT04071236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 175-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (49% lower).

The record links to 4 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04071236 names 20 study sites across 6 states, led by Florida, California, Kansas.

Frequently Asked Questions

What is clinical trial NCT04071236 about?

NCT04071236 is a clinical study titled "Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy". This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 ma...

What is the current status of trial NCT04071236?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2020-10-14. Estimated completion is 2026-04-30.

What conditions does trial NCT04071236 study?

This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Metastatic Malignant Neoplasm in the Bone, Metastatic Castration-resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Lymph Nodes.

What interventions are being tested in trial NCT04071236?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Bone Scan (PROCEDURE), Avelumab (DRUG).

Who is sponsoring clinical trial NCT04071236?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04071236 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IVB Prostate Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04071236's enrollment target sits among peer trials

90 17th of 45 higher than 29 of 45 other Stage IVB Prostate Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IVB Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04071236

Source: ClinicalTrials.gov NCT04071236, the US trial registry maintained by the National Library of Medicine. NCT04071236 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.